Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.

Blanchard P, Pugh TJ, Swanson DA, Mahmood U, Chen HC, Wang X, Graber WJ, Kudchadker RJ, Bruno T, Feeley T, Frank SJ.

Brachytherapy. 2017 Dec 18. pii: S1538-4721(17)30528-7. doi: 10.1016/j.brachy.2017.11.007. [Epub ahead of print]

PMID:
29269207
2.

Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes.

Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):374-382. doi: 10.1016/j.ijrobp.2017.09.050. Epub 2017 Oct 12.

3.

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial.

Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE, Hoffman KE.

Adv Radiat Oncol. 2017 Aug 1;2(3):249-258. doi: 10.1016/j.adro.2017.07.010. eCollection 2017 Jul-Sep.

4.

Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort.

Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA.

BJU Int. 2017 Sep 20. doi: 10.1111/bju.14021. [Epub ahead of print]

PMID:
28941030
5.

Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy.

Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D, Park NI, Coutinho FJ, Whetstone H, Selvadurai HJ, Che C, Luu B, Carles A, Moksa M, Rastegar N, Head R, Dolma S, Prinos P, Cusimano MD, Das S, Bernstein M, Arrowsmith CH, Mungall AJ, Moore RA, Ma Y, Gallo M, Lupien M, Pugh TJ, Taylor MD, Hirst M, Eaves CJ, Simons BD, Dirks PB.

Nature. 2017 Sep 14;549(7671):227-232. doi: 10.1038/nature23666. Epub 2017 Aug 30.

PMID:
28854171
6.

Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas.

Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K, Mansouri S, Karimi S, Sahm F, von Deimling A, Taylor MD, Laperriere NJ, Pugh TJ, Aldape KD, Zadeh G.

Nat Commun. 2017 Aug 4;8(1):186. doi: 10.1038/s41467-017-00174-7.

7.

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis.

Stokes WA, Kavanagh BD, Raben D, Pugh TJ.

Pract Radiat Oncol. 2017 Jul - Aug;7(4):270-278. doi: 10.1016/j.prro.2017.03.011.

PMID:
28673554
8.

Recurrent and functional regulatory mutations in breast cancer.

Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G.

Nature. 2017 Jul 6;547(7661):55-60. doi: 10.1038/nature22992. Epub 2017 Jun 28.

PMID:
28658208
9.

Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers.

Martin GV, Pugh TJ, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Blanchard P, Frank SJ.

Brachytherapy. 2017 Jul - Aug;16(4):761-769. doi: 10.1016/j.brachy.2017.04.004. Epub 2017 May 10.

PMID:
28501429
10.

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, Trudel S, Pugh TJ.

Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.

11.

Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer.

Jackson MW, Amini A, Jones BL, Kavanagh B, Maroni P, Frank SJ, Mahmood U, Kudchadker RJ, Pugh TJ.

Brachytherapy. 2017 Jul - Aug;16(4):790-796. doi: 10.1016/j.brachy.2017.03.007. Epub 2017 Apr 23.

PMID:
28442277
12.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

PMID:
28428191
13.

Data resources for the identification and interpretation of actionable mutations by clinicians.

Prawira A, Pugh TJ, Stockley TL, Siu LL.

Ann Oncol. 2017 May 1;28(5):946-957. doi: 10.1093/annonc/mdx023.

PMID:
28327901
14.

Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging.

Martin GV, Pugh TJ, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Frank SJ.

Brachytherapy. 2017 Jul - Aug;16(4):728-733. doi: 10.1016/j.brachy.2017.02.001. Epub 2017 Mar 9.

PMID:
28284511
15.

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.

J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.

PMID:
28221868
16.

Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database.

Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ.

Urol Oncol. 2017 Jun;35(6):438-446. doi: 10.1016/j.urolonc.2017.01.013. Epub 2017 Feb 15.

PMID:
28214281
17.

A distinct innate lymphoid cell population regulates tumor-associated T cells.

Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, Milea A, Sowamber R, Katz SR, Bernardini MQ, Clarke BA, Shaw PA, Lang PA, Berman HK, Pugh TJ, Lanier LL, Ohashi PS.

Nat Med. 2017 Mar;23(3):368-375. doi: 10.1038/nm.4278. Epub 2017 Feb 6.

18.

Magnetic resonance imaging in prostate brachytherapy: Evidence, clinical end points to data, and direction forward.

Pugh TJ, Pokharel SS.

Brachytherapy. 2017 Jul - Aug;16(4):659-664. doi: 10.1016/j.brachy.2016.12.001. Epub 2017 Feb 1.

PMID:
28161432
19.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, Buxhaku J, Davies H, Faso V, Germain A, Glanville B, Miller VA, Stephens PJ, Janeway KA, Maris JM, Meshinchi S, Pugh TJ, Shern JF, Lipson D.

Cancer Res. 2017 Jan 15;77(2):509-519. doi: 10.1158/0008-5472.CAN-16-1106. Epub 2017 Jan 9.

20.

Reply to J.B. Aragon-Ching and D. Dalela et al.

Rusthoven CG, Jones BL, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2017 Mar 10;35(8):916-917. doi: 10.1200/JCO.2016.70.9220. Epub 2016 Dec 12. No abstract available.

PMID:
27937090
21.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062.

22.

The genomic landscape of schwannoma.

Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y, Landon-Brace N, Tung T, Dowar M, Li T, Bruce JP, Burrell KE, Tonge PD, Alamsahebpour A, Krischek B, Agarwalla PK, Bi WL, Dunn IF, Beroukhim R, Fehlings MG, Bril V, Pagnotta SM, Iavarone A, Pugh TJ, Aldape KD, Zadeh G.

Nat Genet. 2016 Nov;48(11):1339-1348. doi: 10.1038/ng.3688. Epub 2016 Oct 10.

PMID:
27723760
23.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

24.

Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.

Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA.

Am J Clin Oncol. 2016 Sep 15. [Epub ahead of print]

PMID:
27635624
25.

Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.

Bailey SD, Desai K, Kron KJ, Mazrooei P, Sinnott-Armstrong NA, Treloar AE, Dowar M, Thu KL, Cescon DW, Silvester J, Yang SY, Wu X, Pezo RC, Haibe-Kains B, Mak TW, Bedard PL, Pugh TJ, Sallari RC, Lupien M.

Nat Genet. 2016 Oct;48(10):1260-6. doi: 10.1038/ng.3650. Epub 2016 Aug 29.

26.

Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.

Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng FY, Boutros PC, Freedman ML, Walsh MJ, He HH.

Nat Genet. 2016 Oct;48(10):1142-50. doi: 10.1038/ng.3637. Epub 2016 Aug 15.

PMID:
27526323
27.

Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience.

Lim TY, Kudchadker RJ, Wang J, Bathala T, Szklaruk J, Pugh TJ, Mahmood U, Ibbott GS, Frank SJ.

J Contemp Brachytherapy. 2016 Jun;8(3):235-42. doi: 10.5114/jcb.2016.60506. Epub 2016 Jun 13.

28.

Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.

Giannikou K, Malinowska IA, Pugh TJ, Yan R, Tseng YY, Oh C, Kim J, Tyburczy ME, Chekaluk Y, Liu Y, Alesi N, Finlay GA, Wu CL, Signoretti S, Meyerson M, Getz G, Boehm JS, Henske EP, Kwiatkowski DJ.

PLoS Genet. 2016 Aug 5;12(8):e1006242. doi: 10.1371/journal.pgen.1006242. eCollection 2016 Aug.

29.

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788. Epub 2016 Jun 20.

PMID:
27325855
30.

Next generation sequencing-based copy number analysis reveals low prevalence of deletions and duplications in 46 genes associated with genetic cardiomyopathies.

Ceyhan-Birsoy O, Pugh TJ, Bowser MJ, Hynes E, Frisella AL, Mahanta LM, Lebo MS, Amr SS, Funke BH.

Mol Genet Genomic Med. 2015 Dec 16;4(2):143-51. doi: 10.1002/mgg3.187. eCollection 2016 Mar.

31.

Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma.

Bratman SV, Bruce JP, O'Sullivan B, Pugh TJ, Xu W, Yip KW, Liu FF.

JAMA Oncol. 2016 Jun 1;2(6):823-6. doi: 10.1001/jamaoncol.2015.6587. No abstract available.

PMID:
27010835
32.

Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.

Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ.

Brachytherapy. 2016 May-Jun;15(3):274-82. doi: 10.1016/j.brachy.2016.01.003. Epub 2016 Feb 23.

33.

VisCap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data.

Pugh TJ, Amr SS, Bowser MJ, Gowrisankar S, Hynes E, Mahanta LM, Rehm HL, Funke B, Lebo MS.

Genet Med. 2016 Jul;18(7):712-9. doi: 10.1038/gim.2015.156. Epub 2015 Dec 17.

34.

Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy.

Grant SR, Walker GV, Koshy M, Shaitelman SF, Klopp AH, Frank SJ, Pugh TJ, Allen PK, Mahmood U.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):968-75. doi: 10.1016/j.ijrobp.2015.08.036. Epub 2015 Aug 28.

PMID:
26452570
35.

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, O'Brien C, De Carvalho DD.

Cell. 2015 Aug 27;162(5):961-73. doi: 10.1016/j.cell.2015.07.056.

36.

Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome.

Cordeddu V, Yin JC, Gunnarsson C, Virtanen C, Drunat S, Lepri F, De Luca A, Rossi C, Ciolfi A, Pugh TJ, Bruselles A, Priest JR, Pennacchio LA, Lu Z, Danesh A, Quevedo R, Hamid A, Martinelli S, Pantaleoni F, Gnazzo M, Daniele P, Lissewski C, Bocchinfuso G, Stella L, Odent S, Philip N, Faivre L, Vlckova M, Seemanova E, Digilio C, Zenker M, Zampino G, Verloes A, Dallapiccola B, Roberts AE, Cavé H, Gelb BD, Neel BG, Tartaglia M.

Hum Mutat. 2015 Nov;36(11):1080-7. doi: 10.1002/humu.22834. Epub 2015 Aug 3.

37.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

38.

Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.

Davis JW, Ward JF 3rd, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J.

BJU Int. 2016 Jul;118(1):68-76. doi: 10.1111/bju.13193. Epub 2015 Jul 4.

39.

Pugh et al. reply.

Pugh TJ, Banerji S, Meyerson M.

Nature. 2015 Apr 16;520(7547):E12-4. doi: 10.1038/nature14266. No abstract available.

PMID:
25877207
40.

Oncotator: cancer variant annotation tool.

Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, Meyerson M, Getz G.

Hum Mutat. 2015 Apr;36(4):E2423-9. doi: 10.1002/humu.22771. Epub 2015 Mar 16.

PMID:
25703262
41.

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.

Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, Fraser M, Tse K, Poon R, Shih DJ, Baskin B, Ray PN, Bouffet E, Dirks P, von Bueren AO, Pfaff E, Korshunov A, Jones DT, Northcott PA, Kool M, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognár L, Cho BK, Eberhart CG, Conter CF, Fouladi M, French PJ, Grajkowska WA, Gupta N, Hauser P, Jabado N, Vasiljevic A, Jung S, Kim SK, Klekner A, Kumabe T, Lach B, Leonard JR, Liau LM, Massimi L, Pollack IF, Ra YS, Rubin JB, Van Meir EG, Wang KC, Weiss WA, Zitterbart K, Bristow RG, Alman B, Hawkins CE, Malkin D, Clifford SC, Pfister SM, Taylor MD, Tabori U.

Acta Neuropathol Commun. 2014 Dec 24;2:174. doi: 10.1186/s40478-014-0174-y.

42.

A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex.

Tyburczy ME, Jozwiak S, Malinowska IA, Chekaluk Y, Pugh TJ, Wu CL, Nussbaum RL, Seepo S, Dzik T, Kotulska K, Kwiatkowski DJ.

Hum Mol Genet. 2015 Apr 1;24(7):1836-42. doi: 10.1093/hmg/ddu597. Epub 2014 Nov 28.

43.

Proton beam therapy for the treatment of prostate cancer.

Pugh TJ, Lee AK.

Cancer J. 2014 Nov-Dec;20(6):415-20. doi: 10.1097/PPO.0000000000000083. Review.

PMID:
25415688
44.

Proton therapy for seminoma: Case report describing the technique, efficacy, and advantages of proton-based therapy for seminoma.

Haque W, Wages C, Zhu XR, Choi S, Pugh TJ, Frank SJ, Lee A, Mahmood U.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):135-40. doi: 10.1016/j.prro.2014.07.006. Epub 2014 Sep 8. No abstract available.

PMID:
25413401
45.

Local recurrence map to guide target volume delineation after radical prostatectomy.

Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA.

Pract Radiat Oncol. 2014 Nov-Dec;4(6):e239-46. doi: 10.1016/j.prro.2014.02.007. Epub 2014 Apr 16.

PMID:
25407875
46.

Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil.

Pugh TJ, Mahmood U, Swanson DA, Munsell MF, Wang R, Kudchadker RJ, Bruno TL, Frank SJ.

Brachytherapy. 2015 Mar-Apr;14(2):160-5. doi: 10.1016/j.brachy.2014.08.045. Epub 2014 Sep 23.

PMID:
25255712
47.

Establishing high-quality prostate brachytherapy using a phantom simulator training program.

Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, Pugh TJ, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, Frank SJ.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):579-86. doi: 10.1016/j.ijrobp.2014.06.036. Epub 2014 Aug 20.

PMID:
25151539
48.

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.

Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS.

Clin Cancer Res. 2015 Feb 1;21(3):632-41. doi: 10.1158/1078-0432.CCR-13-3310. Epub 2014 Jul 23.

49.

Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences.

Pugh TJ, Yu W, Yang J, Field AL, Ambrogio L, Carter SL, Cibulskis K, Giannikopoulos P, Kiezun A, Kim J, McKenna A, Nickerson E, Getz G, Hoffher S, Messinger YH, Dehner LP, Roberts CW, Rodriguez-Galindo C, Williams GM, Rossi CT, Meyerson M, Hill DA.

Oncogene. 2014 Nov 6;33(45):5295-302. doi: 10.1038/onc.2014.150. Epub 2014 Jun 9.

50.

The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer.

Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE.

Am J Clin Oncol. 2016 Aug;39(4):368-73. doi: 10.1097/COC.0000000000000071.

PMID:
24732810

Supplemental Content

Support Center